The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 11, Issue 3, 2007, Pages 222-232

  Gibert, Juan ^a   Giner, José ^b   Bobes, Julio ^c   Tafalla, Mónica ^d   Herranz, Santiago ^d   Ovejero, Carmen ^e   Rico Villademoros, Fernando ^e  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c UNIVERSIDAD DE OVIEDO   (Spain)

^d ASTRAZENECA   (United Kingdom)

^e Biométrica CRO   (Spain)

Author keywords

Antipsychotics; Naturalistic; Outpatient; Quetiapine; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; ASTHENIA; CARDIOVASCULAR SYMPTOM; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LASSITUDE; LIBIDO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MENTAL PATIENT; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PATIENT CARE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPAIN; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT; WEIGHT GAIN; XEROSTOMIA;

EID: 34548847495     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500601176963     Document Type: Article

References (40)

1. Kane JM. Management issues in schizophrenia. London: Taylor & Francis (A Martin Dunitz Book); 2000.
2. Barbato A. Schizophrenia and public health. World Health Organization, Geneva, 1998. Accessed 27 May 2005 [available at: http://www.who.int/ mental_health/media/en/55.pdf].
3. National Institute of Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002. Accessed 27 May 2005 [available at: http://www.nice.org. uk].
4. McEvoy JP, Scheifler PL, Frances A. Expert Consensus Guideline Series. Treatment of schizophrenia. J Clin Psychiatry 1999;60(Suppl 11):8-80.
5. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. New York: Springer-Verlag; 1998.
6. Fleischhacker WW, Hummer M. Do phase III trials have clinical value? J Clin Psychopharmacol 1999;19:391-2.
7. Norquist G, Lebowitz B, Hyman S. Expanding the frontier of treatment research. Prevention and treatment. Vol. 2, Article 0001a, 1999, posted 21 March. Accessed 27 May 2005 [available at: http://www.journals.apa.org/ prevention/volume2/pre0020001a.html].
8. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992;43:262-5.
9. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(Suppl 10):31-41.
10. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63(Suppl 13):5-11.
11. Arvanitis LA, Miller BG, and the Seroquel Trial 13 study group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
12. Borison RL, Arvanitis LA, Miller BG, and the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69.
13. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, and the Seroquel Study Group. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-57.
14. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
15. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, "Seroquel") and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
16. Emsley RA, Raniwalla J, Bailey PJ, Jones AM, on behalf of the PRIZE Study Group. A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000;15:121-31.
17. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (revised 7 October 2000). HIV Clin Trials 2001;2:92-5.
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-912.
19. Guy W ECDEU. Assessment Manual for Psychopharmacology -Revised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p 218-22.
20. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;334:1-100.
21. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
22. Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry 2000;61:335-43.
23. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2000; CD000967.
24. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209-23.
25. Wirshing DA, Danovitch I, Erhart SM, Pierre JM, Wirshing WC. Update on atypicals: practical tips to manage common side effects. Curr Psychiatry (accessed 3 April 2004) [http://www.currentpsychiatry.com/2003_03/ 0303_antipsych.asp].
26. De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7:59-66.
27. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
28. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
29. Eli Lilly and Company. Zyprexa® olanzapine tablets/US prescribing information. 2005 [http://pilillycom/us/zyprexapipdf].
30. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-90.
31. Brecher M, Leong R, Osterling-Koskinen L, Jones M. Long-term weight change with quetiapine in schizophrenia: data review. Poster presented at the American Psychiatric Association Annual Meeting, Atlanta, GA, USA; 2005. Poster NR262.
32. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004;20:1357-63.
33. Goldstein J, Paulsson B, Sweitzer D, Zhong K. A review of the evidence for somnolence with quetiapine treatment. 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, USA, 21-26 May; 2005. NR 259.
34. Montejo Gonzalez AL, Rico-Villademoros F, Tafalla M, Majadas S, Spanish Working Group for the Study of Psychotropic-related Sexual Dysfunction. A 6-month prospective observational study on the effects of quetiapine on sexual functioning. J Clin Psychopharmacol 2005;25:533-538.
35. Sebastian CS, Glazer W, Buckley PF. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 2004;11:329-42.
36. Mullen J, Jibson MD, Sweitzer D, the QUEST Study Group. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839-54.
37. Montes JM, Ciudad A, Gascon J, Gomez JC, EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:667-74.
38. Lambert M, Haro JM, Novick D, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Outpatient Health Outcomes study. Acta Psychiatr Scand 2005;111:232-43.
39. Tognoni G, Laporte JR. From clinical trails to drug utilization. In: Dukes MNG, editor. Drug utilization studies. Methods and uses. WHO Regional Publications European: World Health Organization; 1993.
40. Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry 2000;61:335-43.